Compare AstraZeneca plc (AZN) vs Fidelity National Information Servcs Inc (FIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Fidelity National Information Servcs Inc — how do they compare? AstraZeneca plc trades at $158.76 (market cap $248.14B), while Fidelity National Information Servcs Inc trades at $42.9 (market cap $22.05B). The key difference: AstraZeneca plc is far larger — about 11.3× Fidelity National Information Servcs Inc's market cap, and Fidelity National Information Servcs Inc pays the higher dividend (4.12%). Which is the better fit depends on your goals.
| AZN | FIS | |
|---|---|---|
Market Cap | $248.14B | $22.05B |
Sector | Health | Technology |
52-Week High | $209.48 | $72.77 |
52-Week Low | $147.06 | $37.72 |
Enterprise Value | $275.41B | $42.56B |
Dividend Yield | 2.01% | 4.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
FIS trades at $42.10, down 0.96% with bearish technical signals. The company shows improving fundamentals with Q2 2026 earnings beat and 5.3% revenue growth, though it lowered full-year guidance. Valuation appears attractive with P/E of 6.57 and P/S of 1.82. Recent expansion into APAC markets and treasury software recognition provide growth catalysts. Cash flow improved significantly from 2025's negative $1.35B to projected positive $188M for 2026.
FIS presents a mixed outlook with strong banking solutions growth offset by capital markets weakness. The 19% upside to consensus price target of $50.18 offers potential, but execution risks remain given the guidance reduction. Investors should weigh the attractive valuation against operational challenges in achieving sustained profitability improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →
